DeepMed Research

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cross-sectional Characterization of Idiopathic Bronchiectasis

Completed

Conditions: Infection
Bronchial Diseases
Respiratory Tract Diseases

First Posted Date: 2010-12-21

Last Posted Date: 2025-05-11

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 275

Registration Number: NCT01264055

Locations: 🇺🇸
Stanford Medical Center, Stanford, California, United States
🇺🇸
Washington University, St. Louis, Saint Louis, Missouri, United States
🇨🇦
St. Michael's Hospital, Toronto, Canada

and more 3 locations

Effects of Lifeskills Workshop on BP in Hypertensive Employees

Phase 2

Completed

Conditions: Hypertension

Interventions: Behavioral: Lifeskills Workshop Intervention

First Posted Date: 2010-12-17

Last Posted Date: 2016-07-29

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 181

Registration Number: NCT01262066

Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression

Phase 4

Completed

Conditions: Hypercholesterolemia
Atherosclerosis

Interventions: Drug: Statins, HMG CoA

First Posted Date: 2010-10-01

Last Posted Date: 2018-11-30

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 230

Registration Number: NCT01212900

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Systolic Blood Pressure Intervention Trial

Not Applicable

Completed

Conditions: Hypertension

Interventions: Drug: Standard control of SBP
Drug: Intensive control of SBP

First Posted Date: 2010-09-21

Last Posted Date: 2021-01-08

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 9361

Registration Number: NCT01206062

Locations: 🇺🇸
Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States

Effects of Rosuvastatin on the Immune System in Healthy Volunteers With Normal Cholesterol

Completed

Conditions: Immune Modulation
Statins
Healthy Volunteers

First Posted Date: 2010-09-14

Last Posted Date: 2018-10-09

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 20

Registration Number: NCT01200836

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia

Phase 1

Completed

Conditions: Aplastic Anemia
Neutropenia
Pancytopenia
Severe Aplastic Anemia

Interventions: Drug: Cyclophosphamide
Drug: Cyclosporine

First Posted Date: 2010-09-01

Last Posted Date: 2017-05-22

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 22

Registration Number: NCT01193283

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines

Completed

Conditions: Healthy Volunteers
Influenza

First Posted Date: 2010-08-31

Last Posted Date: 2025-05-15

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 203

Registration Number: NCT01191853

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia

Phase 1

Completed

Conditions: Neutropenia
Aplastic Anemia
Pancytopenia
Severe Aplastic Anemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2010-08-23

Last Posted Date: 2021-07-02

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1

Registration Number: NCT01187017

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

Phase 2

Recruiting

Conditions: MDS (Myelodysplastic Syndrome)
Severe Aplastic Anemia

Interventions: Device: Miltenyi CD34 Reagent System
Other: Donor derived G-CSF mobilized PBC

First Posted Date: 2010-08-03

Last Posted Date: 2025-05-11

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 120

Registration Number: NCT01174108

Locations: 🇺🇸
University of Maryland, Baltimore (UMB), Baltimore, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

Phase 2

Completed

Conditions: Small Lymphocytic Lymphoma
CLL (Chronic Lymphocytic Leukemia)

Interventions: Drug: Fludarabine Phosphate
Biological: Ofatumumab
Drug: Cyclophosphamide

First Posted Date: 2010-06-16

Last Posted Date: 2023-11-28

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 32

Registration Number: NCT01145209

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy